I agree with Rocky on this point—i.e. in all likelihood, MNTA’s ‘466 patent is no longer in play in the Lovenox patent trial. Fortunately for MNTA, the immateriality of the ‘466 patent in the ongoing litigation doesn’t matter from a practical standpoint (#msg-68471951).